Enveric Biosciences
NASDAQ: ENVBCambridge, US · Delaware corporation
Find your way into Enveric Biosciences
351 people in our graph share verified history with the Enveric Biosciences team — schools, employers, funds. One of them is your warm intro.
Laura Stenmarkunlockedknows Kevin M. Coveney · together at Grant Thornton LLP (overlapped)
×3knows the team · via University of Calgary
×5knows the team · via Grant Thornton LLP
×2knows the team · via UMass Boston
knows the team · via BDO Seidman, LLP
Enveric Biosciences is a biotechnology company developing neuroplastogenic small-molecule drugs for neuropsychiatric and mental health disorders. It uses a proprietary discovery platform called The Psybrary to build an intellectual property portfolio of novel molecules targeting specific mental health indications.
Founders & leadership
KM
Kevin M. CoveneyinChief Financial OfficerKevin M. Coveney is Chief Financial Officer of Enveric Biosciences, a biotechnology company developing neuroplastogenic small-molecule drugs for mental health disorders. He brings over 20 years of experience in biotechnology and life sciences finance, operations, and SEC reporting, with a track record leading finance and accounting functions at biotech start-ups through multiple equity funding rounds.
JE
Joseph E. TuckerinChief Executive Officer and DirectorJoseph Tucker holds a PhD in Biochemistry & Molecular Biology from the University of Calgary and has spent 25 years in biotechnology, leading multiple companies through acquisitions and public listings on NASDAQ and TSX, while raising over $100 million in institutional and alternative financing. He brings expertise in clinical development across neuropsychiatric and other therapeutic areas, regulatory interactions with the FDA, EMA, and Health Canada, and has completed licensing and partnership deals with major biotech firms.
SD
Srinidhi DevanurExecutive Vice Chairman
VP
Viraj PatelChief Financial Officer
BK
Brent KeltonChief Executive Officer
JT
Joseph TuckerinChief Executive Officer and DirectorDr. Joseph Tucker holds a PhD in Biochemistry and Molecular Biology from the University of Calgary and has spent over 25 years in biotechnology leadership, including CEO or executive roles at multiple companies that achieved public listing or acquisition; his background includes clinical development across neurological and respiratory indications, regulatory interactions with major health authorities, and licensing partnerships with large biopharmaceutical firms.
DA
Dimitrios AngelisNamed on SEC filing
JS
James ShadNamed on SEC filing
DL
David LuciNamed on SEC filing
RS
Robert ShawahNamed on SEC filing
Board
MS
Marcus SchabackerBoard director
SD
Reported raises · per SEC filings
Form D private placements$25.9M disclosed across 5 of 8 rounds · 2018–2026
▶$5MraisedMay 2026 · 4 investors · BiotechnologyRule 506(b)
▶$5MraisedMay 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin M. CoveneyExecutive Officer
- Michael SchabackerDirector
- George W. KeglerDirector
- Sheila DeWittDirector
- Joseph E. TuckerExecutive Officer, Director
- Frank PasqualoneDirector
- Michael D. WebbDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Sales commissions
- $350K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedFeb 2026 · 5 investors · BiotechnologyRule 506(b)
▶$1.5MraisedFeb 2026 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael D. WebbDirector
- Sheila DeWittDirector
- Joseph E. TuckerExecutive Officer, Director
- Kevin M. CoveneyExecutive Officer
- Frank PasqualoneDirector
- Marcus SchabackerDirector
- George W. KeglerDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Sales commissions
- $101.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$106.6KraisedDec 2025 · 15 investors · BiotechnologyRule 506(b)
▶$106.6KraisedDec 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sheila DeWittDirector
- George W. KeglerDirector
- Kevin M. CoveneyExecutive Officer
- Marcus SchabackerDirector
- Frank PasqualoneDirector
- Michael D. WebbDirector
- Joseph E. TuckerExecutive Officer, Director
- Offering amount
- $106.6K
- Amount sold
- $106.6K
- Sales commissions
- $217.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedOct 2025 · 12 investors · PharmaceuticalsRule 506(b)
▶Undisclosed amountofferedOct 2025 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marcus SchabackerDirector
- Kevin M. CoveneyExecutive Officer
- Sheila DeWittDirector
- Joseph E. TuckerExecutive Officer, Director
- Frank PasqualoneDirector
- Michael D. WebbDirector
- George W. KeglerDirector
- Sales commissions
- $155.3K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.8MraisedApr 2023 · 2 investors · PharmaceuticalsRule 506(b)
▶$12.8MraisedApr 2023 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph TuckerExecutive Officer, Director
- Bob DagherExecutive Officer
- Marcus SchabackerDirector
- Douglas LindDirector
- Frank PasqualoneDirector
- Peter FacchiniExecutive Officer
- George KeglerDirector
- Michael D. WebbDirector
- Bevin O'NeilDirector
- Kevin CoveneyExecutive Officer
- Avani KanubaddiExecutive Officer
- Offering amount
- $12.8M
- Amount sold
- $12.8M
- Sales commissions
- $560K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.4MofferedFeb 2021 · 6 investors · PharmaceuticalsRule 506(b)
▶$8.4MofferedFeb 2021 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David JohnsonExecutive Officer, Director
- Avani KanubaddiExecutive Officer, Director
- Sol MayerDirector
- Marcus SchabackerDirector
- John Van BuitenExecutive Officer
- George KeglerDirector
- Offering amount
- $8.4M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.2MofferedJan 2021 · 6 investors · PharmaceuticalsRule 506(b)
▶$8.2MofferedJan 2021 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marcus SchabackerDirector
- Sol MayerDirector
- George KeglerDirector
- Avani KanubaddiExecutive Officer
- John Van BuitenExecutive Officer
- David JohnsonExecutive Officer, Director
- Offering amount
- $8.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedAug 2018 · 4 investors · Business ServicesRule 506(b)
▶$6.6MraisedAug 2018 · 4 investors · Business Services
Rule 506(b)Officers, directors & promoters on the filing
- Dimitrios AngelisDirector
- Srinidhi DevanurExecutive Officer, Director
- James ShadDirector
- Viraj PatelExecutive Officer
- David LuciDirector
- Robert ShawahDirector
- Brent KeltonExecutive Officer
- Offering amount
- $6.6M
- Amount sold
- $6.6M
- Sales commissions
- $456.9K
- Placement agents
- A.G.P. / Alliance Global Partners
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Seeking Alpha14 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood13 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Perplexity13 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
TradingView13 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanks12 shared keywordsFinancial analysis and stock research platform.
Interactive Strength Acquires Ergatta11 shared keywordsFidelity offers an online brokerage platform for retail investors to trade US stocks, ETFs, options, mutual funds, bonds, CDs, and crypto ETPs, with $0 commission on online US stock and ETF trades. It provides trading across web, desktop, and mobile alongside research tools, professional coaching, and advisory services.
Companies competing with Enveric Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Enveric Biosciences (NASDAQ: ENVB) deepens Q2 loss while pushing EB-003 toward trialsstocktitan.net · Aug 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 - AOLaol.com · Aug 2026Frequently asked questions
- What does Enveric Biosciences do?
- Enveric Biosciences is a biotechnology company developing neuroplastogenic small-molecule drugs for neuropsychiatric and mental health disorders. It uses a proprietary discovery platform called The Psybrary to build an intellectual property portfolio of novel molecules targeting specific mental health indications.
- How much funding has Enveric Biosciences raised?
- Enveric Biosciences has disclosed $25.9M raised across 5 of its 8 known rounds.
- Where is Enveric Biosciences headquartered?
- Enveric Biosciences is headquartered in Cambridge, US.